Humanized Anti-IL-1R3 Antibodies
AssigneeMab Discovery GmbH
InventorsStephan Fischer, Michael Brandt
Life of this patent
Estimating the term…
Loading patent…
AssigneeMab Discovery GmbH
InventorsStephan Fischer, Michael Brandt
Estimating the term…
The present disclosure relates to humanized antibodies that specifically bind to IL-1R3 or a fragment or derivative thereof or a polypeptide that contains at least a portion of said antibody that is sufficient to confer IL-1R3 binding specificity. Said antibodies inhibit IL-1R3 induced NFkB activity. They also inhibit IL-1alpha, IL-1beta, IL-33, and/or IL-36 stimulated NFkB activity. The disclosure further relates to use of said humanized antibody in the treatment of an IL-1R3 mediated disease such as cancer. The disclosure finally encompasses a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of the antibody according to the invention. The pharmaceutical composition can be used in treating a IL-1R3 mediated disease such as cancer.
Humanized antibody that specifically binds to IL-1R3 or a fragment or derivative thereof that contains at least a portion of said antibody that is sufficient to confer IL-1R3 binding specificity, comprising:
Humanized antibody that specifically binds to IL-1R3 or a fragment or derivative thereof, wherein the antibody comprises a heavy chain variable (VH) region that is at least 90% identical to a VH region selected from the group consisting of VH regions of SEQ ID NO:
Humanized antibody that specifically binds to IL-1R3 or a fragment or derivative thereof, wherein the antibody comprises a light chain variable (VL) region that is at least 90% identical to a VL region selected from the group consisting of VL regions of SEQ ID NO:
Humanized antibody that specifically binds to IL-1R3, or a fragment or derivative thereof that contains at least a portion of said antibody that is sufficient to confer IL-1R3 binding specificity, and inhibits IL-1R3 induced NFkB activity.
Dependencies are inferred from the claim text.